Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc. is positioned favorably due to its focus on developing proprietary medicines for significant unmet medical needs in oncology and COVID-19 treatment, with promising candidates like Endoxifen and the inhaled and nasal spray formulations for COVID-19. The company exhibits an attractive current valuation, evident from the upward adjustments in price targets based on net present value (NPV) analyses, indicating strong potential for future growth. Additionally, the anticipated achievement of key clinical milestones is expected to act as a catalyst for stock performance, further enhancing the company's positive outlook.

Bears say

Atossa Therapeutics Inc reported a net loss of $8.7 million, with an earnings per share (EPS) of $(0.07), aligning with previous losses of $8.4 million and an EPS of $(0.07) in earlier periods. The company faces significant risks that could impede its ability to meet financial targets, including balance sheet and liquidity concerns, potential failures in demonstrating the safety and efficacy of its product candidates, and challenges related to regulatory approvals and commercialization. Additionally, external factors such as competition, macroeconomic fluctuations, and changing investor sentiments toward biotech stocks further contribute to the negative outlook on the company’s stock performance.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.